T-cell engagers

News

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.

News

Ouro makes debut with $120m for autoimmune disease TCEs

Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.

Oncology

ASCO 2024 - Matteo Levisetti

ASCO 2024 marked the 10th anniversary of checkpoint inhibitors, which powerfully changed the nature of cancer immunotherapy.

Gilead buys autoimmune disease biotech Ouro for $2.2bn

Kidney biotech R1's $78m debut, and other biofinancings

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Ouro makes debut with $120m for autoimmune disease TCEs

ASCO 2024 - Matteo Levisetti

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

T-cell engagers

Editor's Picks